Shkreli inflated price of life-saving drug from federal prison, FTC says
14-08-2020
Shkreli says he isn’t responsible for Daraprim ‘monopoly’
30-07-2020
Mark Van Scyoc / Shutterstock.com
The US Federal Trade Commission (FTC) should avoid reviewing communications between Martin Shkreli and his attorneys, but these are not protected under the Privacy Act, a New York federal judge has ruled.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
FTC, Federal Trade Commission, Privacy Act, Martin Shkreli, Vyera Pharmaceuticals, antitrust, Daraprim, monopoly, communications, attorney, BOP
